

PFIZER INC
Form 8-K
February 23, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 23, 2017**

PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	1-3619 (Commission File Number)	13-5315170 (I.R.S. Employer Identification No.)
235 East 42nd Street New York, New York (Address of principal executive offices)		10017 (Zip Code)

Registrant's telephone number, including area code: **(212) 733-2323**

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item Departure of Directors or Certain Officers;
5.02 Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of**

Certain Officers

On February 23, 2017, the Board of Directors of Pfizer Inc. (the "Company") elected Ronald E. Blaylock to serve as a member of the Company's Board of Directors, effective immediately. In addition, he was elected to the Corporate Governance Committee and the Science and Technology Committee of the Board.

Mr. Blaylock has been provided an indemnification agreement and will receive compensation in accordance with the Company's standard arrangements for non-employee directors.

The press release, dated February 23, 2017, announcing the election of Mr. Blaylock is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of the Company, dated February 23, 2017

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Madden
Margaret M. Madden

Title: Senior Vice President and Corporate Secretary
Chief Governance Counsel

Dated: February 23, 2017

EXHIBIT INDEX

Number Description

99.1 Press Release of the Company, dated February 23, 2017